Donald Drakeman, JD, PhD
Steve Holmes, PhD
Capella Bioscience was created with the mission to advance monoclonal antibody (mAb) therapeutics in autoimmune diseases with high unmet need. The lead programs are CBS001, currently in Phase 1, and CBS004, currently undergoing IND-enabling studies, for the treatment of rare inflammatory disorders.
We are developing CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT (known as TNFSF14) for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, we are developing CBS004, a therapeutic mAb to target BDCA-2 for the treatment of lupus erythematosus, both systemic and cutaneous (SLE and CLE, respectively), and systemic sclerosis (SSc).